Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

    Thumbnail
    Download
    Citations
    Web of Science
    Altmetric
    1
    Author
    Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; Atkinson, V; Millward, M; Khou, M; Diem, S; Ramanujam, S; ...
    Date
    2017-04-11
    Source Title
    British Journal of Cancer
    Publisher
    NATURE PUBLISHING GROUP
    University of Melbourne Author/s
    McArthur, Grant
    Affiliation
    Melbourne Medical School
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M. C., Parakh, S., Cebon, J., Long, G. V., Carlino, M. S. & Klein, O. (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. BRITISH JOURNAL OF CANCER, 116 (8), https://doi.org/10.1038/bjc.2017.59.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/258389
    DOI
    10.1038/bjc.2017.59

    Export Reference in RIS Format     

    Publisher licence
    CC BY-NC-SA
    Collections